All News

As we start to use MRI to treat nr-axSpA outside of the tertiary centers, we’ve got to ask - how good are the local readers compared to specialized ones? Caution and more community radiologist education required #EULAR2019 THU0359 from ASAS classification cohort @RheumNow https://t.co/7Qqp1z0chO
David Liew drdavidliew ( View Tweet)
Is GCA seasonality present in the Southern Hemisphere (summer starts in December)? Maybe it’s when our pathologists are feeling summer-generous... small numbers but nice work from @winkler_gemma #EULAR2019 THU0323 @RheumNow https://t.co/v9iT965BAM
David Liew drdavidliew ( View Tweet)
Congratulations to @EricMattesonMD on becoming a honorary member of the EULAR! Well deserved! #EULAR2019 https://t.co/yrjhfS2abB
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
First day in Numbers 🔢 #EULAR2019 👉🏻 More than 9⃣ million of impressions 👉🏻 Almost 4⃣ thousand Tweets 🐦 👉🏻 From 965 participants #RheumaTwitters Data from the Healthcare Hashtag Project - Symplur @symplur 🔗 https://t.co/Ib2D1WP09q https://t.co/GIncIijmFs

Links:

Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
Interstitial lung disease occurs in about half of all patients with systemic sclerosis; of these, about one-third will experience lung disease progression. "[Patients] needs to be screened [with high resolution CT] because a lung function test is not enough." #EULAR2019

CreakyJoints.org CreakyJoints ( View Tweet)

GiACTA part 2 - the morning has arrived! Disappointment or hope for tocilizumab in GCA? I'll be live tweeting it as we go. Here's the abstract to start you off: https://t.co/qtH8E5rVrB #EULAR2019 OP0140 @RheumNow

Links:

David Liew drdavidliew ( View Tweet)

Positive results presented so yes, interest in molecules beyond JAKi. All good for people esp once patents finish! #EULAR2019 https://t.co/beW9GblqdF

Links:

Dr Irwin Lim _connectedcare ( View Tweet)

Look at this list of Biosimilars to TNFis! How would you decide what to use? The cost to the payer & what might be imposed? #EULAR2019 https://t.co/DhshdumsXO
Dr Irwin Lim _connectedcare ( View Tweet)
In GCA, concomitant PMR might separate out better prognosis phenotype. Mortality benefit in PMR-relevant OR 0.68 (0.58-0.80). Phenotypes important moving forward in therapeutic selection? #EULAR2019 THU0295 from U La Paz, Madrid @RheumNow https://t.co/4viMygbTcP
David Liew drdavidliew ( View Tweet)
Good morning #EULAR2019 delegates. Come by and visit, meet the Editor! https://t.co/DagNuxGfDq
The Journal of Rheumatology jrheum ( View Tweet)
Cool data presented at #EULAR2019 by @CreakyJoints #ArthritisPower https://t.co/ZtFUsEiboR

Links:

Seth D. Ginsberg SethSaidSo ( View Tweet)

Think: Do you really need to repeat another ANA test?🤔 👉🏼Repeat Antinuclear #antibody testing after a negative result had limited utility in diagnosis of ANA associated rheumatological conditions Via Ai Li Yeo #EULAR2019 OP0020 @RheumNow #immunology #rheumedu https://t.co/eK7GTRn8Z7
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
OP0315. In ERA CATCH cohort fatigue final improvement lags behin remission by approx 6 months. So tell pts with RA that maximal improvement in fatigue lags a bit. #EULAR2019 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

New #EULAR2019 data finds a link between vitamin D deficiency and disease activity among #spondyloarthritis patients. This could help explain the cause of "osteoporosis related to spondyloarthritis, and may adversely affect the patient’s functional status and quality of life."

CreakyJoints.org CreakyJoints ( View Tweet)

There is no clear relationship between ANCA titer and vasculitis relapse, but patients with negative ANCA seem to have less relapses. #EULAR2019 #vasculitis

Jesús Loarce JesusLoarce ( View Tweet)

Congratulations to @Yuz6Yusof, awarded best #EULAR2019 abstract! His work 👉🏼recommended monitoring immunoglobulins baseline & b4 rituximab cycles to identify patients at risk of severe infections https://t.co/bOdwVLlXnL
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Interesting discussion about nocebo effect when swapping to biosimilars. “Cheaper” may trigger this. Health professionals need to understand we are salespeople in many situations. Language, trust, style matter. #EULAR2019 https://t.co/29GP6cmXhQ
Dr Irwin Lim _connectedcare ( View Tweet)
Optimal bimekizumab dose in PsA still remains to be determined.

Stefan Siebert StefanSiebert1 ( View Tweet)

Ritchlin: Bimekizumab (anti-IL17A & F) Phase 2B in active PsA = rapid response but also further increases wk12 to wk20 and sustained to wk48. #eular2019 @RheumNow https://t.co/yblCNmTxR4
Stefan Siebert StefanSiebert1 ( View Tweet)
@_connectedcare @RheumNow Certainly good rationale for also blocking IL-17F from pathophysiology point of view but will need to see if leads to diffs in RCTs…may also be important for IBD/other conditions

Stefan Siebert StefanSiebert1 ( View Tweet)

×